Danaher (NYSE:DHR) Price Target Cut to $277.00

Danaher (NYSE:DHR) had its target price cut by Robert W. Baird from $278.00 to $277.00 in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have an outperform rating on the conglomerate’s stock.

Several other research firms have also recently weighed in on DHR. Stifel Nicolaus boosted their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. The Goldman Sachs Group raised their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Stephens initiated coverage on shares of Danaher in a report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 price target on the stock. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Finally, Barclays lifted their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Trading Down 1.1 %

Shares of Danaher stock opened at $245.39 on Wednesday. The firm has a market capitalization of $181.76 billion, a PE ratio of 41.59, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $269.52 and its 200 day moving average is $260.42. Danaher has a 1 year low of $182.09 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.02 earnings per share. Equities research analysts forecast that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock valued at $8,400,897 over the last ninety days. 11.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Danaher

Institutional investors have recently bought and sold shares of the stock. Benjamin Edwards Inc. grew its stake in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 38 shares in the last quarter. Wedge Capital Management L L P NC grew its position in Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. lifted its position in shares of Danaher by 3.4% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after buying an additional 40 shares in the last quarter. Trust Co of Kansas boosted its stake in shares of Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after buying an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. grew its holdings in shares of Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after acquiring an additional 40 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.